Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Felezonexor - Stemline Therapeutics

Drug Profile

Felezonexor - Stemline Therapeutics

Alternative Names: CBS 9106; SL-801

Latest Information Update: 09 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CanBas
  • Developer Stemline Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Exportin-1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Haematological malignancies

Most Recent Events

  • 01 Oct 2019 Efficacy and safety data from a phase I study in Solid tumours presented at the 43rd European Society for Medical Oncology Congress (ESMO-2019)
  • 08 May 2019 Felezonexor is still in phase I trials for Solid-tumours (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (PO, Tablet)
  • 28 Mar 2019 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top